Current Oncology Reports

, Volume 10, Issue 1, pp 47–53

The clinical management of BRCA1 and BRCA2 mutation carriers


DOI: 10.1007/s11912-008-0008-9

Cite this article as:
Gulati, A.P. & Domchek, S.M. Curr Oncol Rep (2008) 10: 47. doi:10.1007/s11912-008-0008-9


Mutations in the cancer susceptibility genes BRCA1 and BRCA2 are associated with significantly increased risks of breast and ovarian cancer. Fortunately, effective strategies are available to reduce these risks, including genetic testing, which is an important consideration in determining management of patients with a strong family history of cancer. This article reviews the current evidence for risk-reducing strategies in BRCA1 and BRCA2 mutation carriers and outlines future research directions. In particular, screening controversies and current guidelines are discussed, as are issues related to prophylactic mastectomy and oophorectomy.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Cancer Risk Evaluation ProgramUniversity of Pennsylvania, Abramson Cancer CenterPhiladelphiaUSA